Patent Expiry

Patent/Exclusivity Expiry: NERLYNX

Other upcoming events for PBYI

Phase 2 StartPhase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: NERLYNX — PBYI Patent Expiry | BioSniper